Literature DB >> 21660584

Prevalence of pulmonary hypertension in patients with idiopathic pulmonary fibrosis: correlation with physiological parameters.

D Papakosta1, G Pitsiou, Z Daniil, M Dimadi, E Stagaki, A Rapti, K Antoniou, A Tzouvelekis, T Kontakiotis, S Tryfon, V Polychronopoulos, D Bouros.   

Abstract

The aim of this study was to prospectively evaluate the prevalence of pulmonary hypertension (PH) in patients with idiopathic pulmonary fibrosis (IPF). One hundred thirty-nine patients (101 male, mean age = 68.6 ± 9 years), with confirmed IPF and who were admitted to eight Pulmonary Departments in Greece between November 2005 and December 2006 were included in the study. Pulmonary artery systolic pressure (PASP) was estimated by echocardiography, and PH was defined as PASP > 36 mmHg. We compared demographics, pulmonary function tests, NYHA functional status, 6-min walk distance (6MWD), B-type natriuretic peptide (BNP), PaO(2), and P(A-a)O(2) at rest data between patients with PH and without PH (PASP ≤ 36 mmHg). Increased estimated right ventricular systolic pressure was present in 55% of patients (mean PASP = 47.1 ± 11.2 mmHg vs. 30.3 ± 3.8 mmHg, respectively). Patients with PH had a lower but not statistically significant DL(CO) (47.1 ± 18.8 vs. 52.5 ± 20.1), lower PaO(2) at rest (64.6 ± 12.2 vs. 71.1 ± 11.3, P = 0.004), and lower mean 6MWD (282 ± 118 vs. 338 ± 91, P = 0.007). Significant differences were also observed in the NYHA functional status between the two groups (P = 0.02). Statistically significant correlations were observed between PASP and PaO(2) at rest (r = -0.331, P = 0.00), P(A-a)O(2) at rest (r = 0.494, P = 0.00)(,) 6MWD (r = -0.264, P = 0.01), SpO(2) at rest (r = -0.293, P = 0.00), SpO(2) at the end of exercise (r = -0.364, P = 0.00), and also BNP values (r = 0.319, P = 0.01). Moreover, PaO(2) (P = 0.02), P(A-a)O(2) (P = 0.005), and SpO(2) at the end of exercise (P = 0.023) were independent predictors of the presence of estimated PH. Using Doppler echocardiography as a screening tool for the estimation of PH, we found that PH is common in patients with IPF. Gas exchange parameters at rest and exercise desaturation might indicate underlying PH in IPF.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21660584     DOI: 10.1007/s00408-011-9304-5

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  29 in total

1.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

Review 2.  Diagnostic value of transthoracic Doppler echocardiography in pulmonary hypertension: a meta-analysis.

Authors:  Rui Feng Zhang; Lin Zhou; Guo Feng Ma; Fang Chun Shao; Xiao Hong Wu; Ke Jing Ying
Journal:  Am J Hypertens       Date:  2010-09-09       Impact factor: 2.689

3.  Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis.

Authors:  Christopher J Lettieri; Steven D Nathan; Scott D Barnett; Shahzad Ahmad; Andrew F Shorr
Journal:  Chest       Date:  2006-03       Impact factor: 9.410

4.  Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension.

Authors:  Micah R Fisher; Paul R Forfia; Elzbieta Chamera; Traci Housten-Harris; Hunter C Champion; Reda E Girgis; Mary C Corretti; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2009-01-22       Impact factor: 21.405

5.  Brain natriuretic peptide is a prognostic parameter in chronic lung disease.

Authors:  Hanno H Leuchte; Rainer A Baumgartner; Michal El Nounou; Michael Vogeser; Claus Neurohr; Michael Trautnitz; Juergen Behr
Journal:  Am J Respir Crit Care Med       Date:  2006-01-13       Impact factor: 21.405

6.  Impact of pulmonary hypertension on gas exchange and exercise capacity in patients with pulmonary fibrosis.

Authors:  Sven Gläser; Oliver Noga; Beate Koch; Christian F Opitz; Bernd Schmidt; Bettina Temmesfeld; Marcus Dörr; Ralf Ewert; Christoph Schäper
Journal:  Respir Med       Date:  2008-09-18       Impact factor: 3.415

7.  Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis.

Authors:  Steven D Nathan; Oksana A Shlobin; Shahzad Ahmad; Jim Koch; Scott D Barnett; Niv Ad; Nelson Burton; Kevin Leslie
Journal:  Respiration       Date:  2008-01-24       Impact factor: 3.580

Review 8.  Pulmonary hypertension in interstitial lung disease.

Authors:  J Behr; J H Ryu
Journal:  Eur Respir J       Date:  2008-06       Impact factor: 16.671

9.  Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant.

Authors:  A F Shorr; J L Wainright; C S Cors; C J Lettieri; S D Nathan
Journal:  Eur Respir J       Date:  2007-07-11       Impact factor: 16.671

10.  Left ventricular diastolic dysfunction in idiopathic pulmonary fibrosis: a tissue Doppler echocardiographic [corrected] study.

Authors:  C E Papadopoulos; G Pitsiou; T D Karamitsos; H I Karvounis; T Kontakiotis; G Giannakoulas; G K Efthimiadis; P Argyropoulou; G E Parharidis; D Bouros
Journal:  Eur Respir J       Date:  2007-12-05       Impact factor: 16.671

View more
  11 in total

1.  Should we routinely screen patients with idiopathic pulmonary fibrosis for nocturnal hypoxemia?

Authors:  Georgia Pitsiou; Vasilis Bagalas; Afroditi Boutou; Ioannis Stanopoulos; Paraskevi Argyropoulou-Pataka
Journal:  Sleep Breath       Date:  2012-05-06       Impact factor: 2.816

2.  Influence of pulmonary hypertension on survival in advanced lung disease.

Authors:  Don Hayes; Sylvester M Black; Joseph D Tobias; Heidi M Mansour; Bryan A Whitson
Journal:  Lung       Date:  2015-02-18       Impact factor: 2.584

3.  Critical exacerbation of idiopathic pulmonary fibrosis after transcatheter aortic valve implantation: Need for multidisciplinary care beyond "heart team".

Authors:  Yoichiro Sugizaki; Shumpei Mori; Yuichi Nagamatsu; Tomomi Akita; Akira Nagasawa; Takayoshi Toba; Masatsugu Yamamoto; Tatsuya Nishii; Norihiko Obata; Yoshikatsu Nomura; Hiromasa Otake; Toshiro Shinke; Yutaka Okita; Ken-Ichi Hirata
Journal:  J Cardiol Cases       Date:  2018-08-17

4.  Echocardiographic characteristics of patients with antisynthetase syndrome.

Authors:  Jaimie L Bryan; Ralph Matar; Abheek Raviprasad; Veronica Kuteyeva; Eduardo Milla; Omkar Begateri; Divya Patel; Diana G Manjarres; Saminder S Kalra; Jeffrey Robinson; Akram Khan; Raju Reddy
Journal:  Pulm Circ       Date:  2022-04-27       Impact factor: 2.886

5.  Incidence and clinical characteristics of pulmonary hypertension in patients with idiopathic pulmonary fibrosis.

Authors:  Wei Yan; Li-Ying Peng; Cheng-Jun Ban; Xue-Feng Xu; Min Zhu; Yan Liu; Shu Zhang; Zhen-Guo Zhai; Chen Wang; Hua-Ping Dai
Journal:  Chin Med J (Engl)       Date:  2015-04-05       Impact factor: 2.628

6.  The Clinical Efficacy of Pulmonary Hypertension-Specific Agents in Idiopathic Pulmonary Fibrosis: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.

Authors:  Jonghoo Lee; Jae Uk Song
Journal:  J Korean Med Sci       Date:  2020-03-02       Impact factor: 2.153

7.  Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline.

Authors:  Susan S Jacobs; Jerry A Krishnan; David J Lederer; Marya Ghazipura; Tanzib Hossain; Ai-Yui M Tan; Brian Carlin; M Bradley Drummond; Magnus Ekström; Chris Garvey; Bridget A Graney; Beverly Jackson; Thomas Kallstrom; Shandra L Knight; Kathleen Lindell; Valentin Prieto-Centurion; Elisabetta A Renzoni; Christopher J Ryerson; Ann Schneidman; Jeffrey Swigris; Dona Upson; Anne E Holland
Journal:  Am J Respir Crit Care Med       Date:  2020-11-15       Impact factor: 21.405

8.  Pulmonary hypertension in patients with idiopathic pulmonary fibrosis - the predictive value of exercise capacity and gas exchange efficiency.

Authors:  Sven Gläser; Anne Obst; Beate Koch; Beate Henkel; Anita Grieger; Stephan B Felix; Michael Halank; Leonhard Bruch; Tom Bollmann; Christian Warnke; Christoph Schäper; Ralf Ewert
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

Review 9.  Managing comorbidities in idiopathic pulmonary fibrosis.

Authors:  Blair G Fulton; Christopher J Ryerson
Journal:  Int J Gen Med       Date:  2015-09-22

Review 10.  Therapeutic Approach to Adult Fibrotic Lung Diseases.

Authors:  Ayodeji Adegunsoye; Mary E Strek
Journal:  Chest       Date:  2016-08-10       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.